stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) Shares outstanding
Amylyx Pharmaceuticals, Inc.'s shares outstanding at the end of fiscal 2025 was $94.6M, up 38.8% from $68.1M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $111.2M. Over the past ten years it has ranged from $6.1M (fiscal 2020) to $94.6M (fiscal 2025) — the current reading is the highest in ten years. Amylyx Pharmaceuticals, Inc. ranks 29th of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $94.6M | 38.78% |
| FY2024 | $68.1M | (2.64%) |
| FY2023 | $70.0M | 19.65% |
| FY2022 | $58.5M | 788.14% |
| FY2021 | $6.6M | 8.36% |
| FY2020 | $6.1M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $111.2M | 0.57% |
| Mar 2026 | $110.6M | 16.92% |
| Dec 2025 | $94.6M | 1.32% |
| Sep 2025 | $93.3M | 4.71% |
| 19 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| HIMS Hims & Hers Health, Inc. compare | $231.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $214.3M |
| TRLV Trulieve Cannabis Corp. compare | $200.6M |
| PRGO Perrigo Company plc compare | $139.4M |
| SUPN Indivior Pharmaceuticals Inc. compare | $122.0M |
| AMLX Amylyx Pharmaceuticals, Inc. | $111.2M |
| LQDA Liquidia Corporation compare | $101.4M |
| PBH Prestige Consumer Healthcare Inc. compare | $47.6M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on AMLX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement